Table 1.
Baseline characteristics
| Characteristics | Full dose, N = 28 | Escalating dose, N = 34 | P-value |
|---|---|---|---|
| Age (years), mean (SD) | 40.7 (8.9) | 39.7 (8.2) | 0.68 |
| Male gender, no. (%) | 7 (25%) | 12 (35.3%) | 0.38 |
| Habits | |||
| Smoker, no. (%) | 3/18 (16.7%) | 6/22 (27.3%) | 0.42 |
| Alcohol consumption, no. (%) | 2/19 (10.5%) | 6/22 (27.3) | 0.18 |
| Comorbidities | |||
| Hypertension, no. (%) | 1 (3.6%) | 1 (2.9%) | 0.89 |
| Diabetes, no. (%) | 1 (3.6%) | 0 (0%) | 0.27 |
| Obesity, no. (%) | 3/26 (11.5%) | 2/33 (6.1%) | 0.45 |
| Cerebrovascular disease, no. (%) | 1 (3.6%) | 1 (2.9%) | 0.89 |
| Liver disease, no. (%) | 0 | 1 (2.9%) | 0.36 |
| Renal disease, coronary heart disease, HIV, and transplantation | 0 | 0 | – |
| Clinical stage | |||
| Indeterminate form | 22 (78.6%) | 25 (73.5%) | 0.64 |
| Cardiac form, no. (%) | 6 (21.4%) | 9 (26.4%) | 0.64 |
| Gastrointestinal form, no. (%) | 0 | 0 | – |
no. = number. Data are no./number tested (%) of patients, unless otherwise indicated.